Frank Rahmani

• Representation of underwriters, including Goldman Sachs and Morgan Stanley, in connection with Contineum Therapeutics initial public offering with aggregate proceeds of over $110 million.
• Represented Biodesix, Inc., a leading data-driven diagnostic solutions company with a focus in lung disease, on its $72 million initial public offering and subsequent equity and venture debt financings with aggregate proceeds of over $150 million.
• Representation of underwriters, including Goldman Sachs, Morgan Stanley and Citi, in connection with Klaviyo's initial public offering with aggregate proceeds of $659 million.
• Represented Pharvaris, a clinical stage biotechnology company, on its $66 million Series B financing, and the underwriters in the $190 million initial public offering and $300 million follow-on offering of Pharvaris.
• Represented IO Biotech, a clinical-stage biopharmaceutical company, on its $115.1 million initial public offering and subsequent $75 million PIPE financing with participation by investors including Lundbeckfonden, Kurma, Vivo Capital, Samsara BioCapital, and Novo Holdings.
• Represented Pyxis Oncology, a clinical stage biotechnology company, on its $168 million initial public offering and subsequent acquisition of Apexigen.
• Represented Roche in its investment in Freenome, a multiomics platform based lifesciences company, with aggregate proceeds from Roche and other investors in excess of $840 million.
• Represented Close The Loop, an Australian publicly listed company, in its expansion and acquisition of US assets and entities, including ISP Tek Service and Captive Trading, and related financings.
• Represented VERO Biotech, a medical technology company, on multiple preferred equity and debt financings raising over $250 million.
• Represented Akura Medical, Laza Medical, and Myra Vision, medical technology companies, on their preferred stock financing, raising $60 million, $36 million, and $25 million, respectively.
• Represented Supira Medical, a developer of medical devices, on its preferred stock financings, raising over $110 million in the aggregate.
• Represented Atia Vision Inc., an ophthalmology focused company, in its $42 million Series E financing led by Cormorant Asset Management with participation by The Capital Partnership, PA MedTech VC Fund, AMED Ventures, and Shifamed Angel investors.
• Represented Venus Medtech (Hangzhou) Inc., a leading, innovative Chinese structural heart disease treatment company, in its acquisition of Cardiovalve Ltd., an Israel-based, transcatheter mitral and tricuspid valve treatment company, for aggregate consideration of up to $300 million.
• Represented Morgan Stanley, Jefferies, and Cowen as the lead underwriters in the US$129.4 million initial public offering by Immuneering Corporation, a biopharmaceutical company, and representation of underwriters in follow-on underwritten offering of Immuneering.
• Represented the underwriters in the US$198.7 million initial public offering by Tyra Biosciences, Inc., a precision oncology company. BofA Securities, Jefferies, and Cowen acted as the joint book-running managers.
• Represented Arvelle Therapeutics, a biotechnology company, on its
  • formation and subsequent $207 million combined equity and product financing; and
  • sale to Angelini Pharma for a total cash consideration of up to $960 million.
• Represented Outset Medical, a medical technology company, on its
  • $125 million Series E financing;
  • $278 million initial public offering;
  • $212 million secondary public offering; and
  • $365.8 million follow-on public offering.
• Represented Tempest Therapeutics, Inc., a privately held, clinical-stage oncology company, in its merger (i.e. reverse merger) with Millendo Therapeutics, Inc., a public company, in an all-stock transaction with the combined company being listed on NASDAQ as Tempest Therapeutics.
• NuVera Medical, Inc., a medical technology company, in connection with its acquisition by Biosense Webster, part of the Johnson & Johnson family of companies.
• Represented Immunovant, a clinical-stage biotechnology company, on its agreement to merge with Health Sciences Acquisition Corporation, a special purpose acquisition company, and subsequent $139 million underwritten public offering.
• Represented Axovant Gene Therapy on its $362.3 million initial public offering and multiple follow-on public offerings. Axovant is a clinical-stage biotechnology company focused on the treatment of neurological and neuromuscular diseases.
• Represented Dermavant, a biopharmaceutical company focused on dermatology, in its formation and acquisition of assets from GSK for total consideration of €250 million.
• Represented Myovant Sciences on its formation and license transaction from Takeda and subsequent $218 million initial public offering. Myovant Sciences is a biopharmaceutical company focused on the innovative treatment of women’s health diseases and other endocrine-related disorders.
• Represented Urovant on its initial public offering of $100 Million. Urovant is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for urologic conditions.
• Represented Venus Medtech, a publicly listed medical technology company, on its acquisition of Keystone Heart, a medical device company developing and manufacturing cerebral embolic protection (CEP) devices, and multiple collaboration and minority investments, including strategic investment in Pi-Cardia Ltd.
• Represented Vineti, a commercial stage cloud-based platform for cells and gene therapies, on multiple financings including its $68 million Series C financing.
• Represented CardioMEMS, a medical technology company that has developed a proprietary wireless sensing and communication technology, on its acquisition by St. Jude Medical for $455 million.
• Represented OnCore Biopharma on its merger with Tekmira Pharmaceuticals, initially valued at $1.1 billion, to create a new company (Arbutus) focused on developing a cure for people with chronic hepatitis B virus.
• Represented RFS Pharma on its merger with Cocrystal Pharma initially valued at $800 million. Cocrystal Pharma is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, hepatitis C viruses, coronaviruses and noroviruses.
• Represented the underwriters on the $102 million initial public offering of WAVE Life Sciences, a biotechnology company.
• Represented underwriters on Establishment Lab’s $76.9 million initial public offering. Jefferies and Cowen and Company acted as the lead book-running managers.

*Some of the matters above were handled prior to joining Sidley.